Institution statistics

INSTITUT GUSTAVE ROUSSY - France

Ranking results:

Past rankings:

2018
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding per Partner:	> 1000
Total Number of Projects:	> 1000
Networking Rank (Reputation):	900-1000
2015
Criterium:	Position:
Overall Score:	> 1000
Networking Rank (Reputation):	> 1000
2012
Criterium:	Position:
Overall Score:	400-500
Total Project Funding:	400-500
Total Project Funding per Partner:	300-400
Total Number of Projects:	65
Networking Rank (Reputation):	500-600
Networking Rank (Reputation):	500-600
Partner Constancy:	46
Project Leadership Index:	75
Diversity Index:	18
2011
Criterium:	Position:
Overall Score:	800-900
Total Project Funding:	100-200
Total Project Funding per Partner:	200-300
Total Number of Projects:	200-300
Networking Rank (Reputation):	200-300
Partner Constancy:	100-200
Project Leadership Index:	600-700
Diversity Index:	> 1000
2009
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding:	600-700
Total Project Funding per Partner:	700-800
Total Number of Projects:	> 1000
Networking Rank (Reputation):	> 1000
Partner Constancy:	600-700
Project Leadership Index:	500-600
Diversity Index:	> 1000
2008
Criterium:	Position:
Overall Score:	400-500
Total Project Funding:	> 1000
Total Project Funding per Partner:	> 1000
Total Number of Projects:	> 1000
Networking Rank (Reputation):	> 1000
Partner Constancy:	600-700
Project Leadership Index:	500-600
Diversity Index:	500-600
2007
Criterium:	Position:
Overall Score:	> 1000
Total Project Funding:	400-500
Total Project Funding per Partner:	300-400
Total Number of Projects:	600-700
Networking Rank (Reputation):	> 1000
Partner Constancy:	400-500
Project Leadership Index:	400-500
Diversity Index:	> 1000

Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 55
As coordinator: 6
As participant: 46
Sole participant: 3
Coordinator / Participant Ratio: 0.13^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2020	0	7.999.949	425.750		1
2019	14.994.551	6.999.989	2.677.750	1	1
2018	0	12.436.859	540.750		1
2017	0	16.523.625	1.086.240		3
2016	1.500.000	0	1.500.000	1
2015	0	7.476.725	262.876		2
2013	2.998.355	11.662.081	1.517.283	1	2
2012	268.555	25.088.618	2.270.829	1	5
2011	0	63.192.794	4.425.298		11
2009	0	15.551.032	940.021		2
2008	5.228.003	279.931	611.993	1	1
2007	0	11.692.460	789.960		2
2006	3.415.414	9.432.600	759.664	1	1
2005	0	24.052.468	1.092.789		5
2004	0	21.493.900	617.253		5
2003	892.993	0	148.832	1
2002	1.909.090	3.875.479	706.653	1	2
2001	75.000	1.815.000	280.250	1	2

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
KAROLINSKA INSTITUTE	15
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	12
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE	11
INSTITUT CURIE	10
UNIVERSITY OF BIRMINGHAM	10
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER	8
UNIVERSITY OF NEWCASTLE UPON TYNE	8
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	7
CHARITE UNIVERSITAETSMEDIZIN BERLIN	6
INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL	6
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE	6
UNIVERSITY COLLEGE LONDON	6
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	5
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	5
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III	5
ISTITUTO GIANNINA GASLINI	5
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI	5
LEIDEN UNIVERSITY MEDICAL CENTER	5
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN	5
UNIVERSITA DEGLI STUDI DI TORINO	5
ACADEMISCH ZIEKENHUIS LEIDEN	4
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS	4
DANISH CANCER SOCIETY	4
GSF FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT	4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	4
INSTITUT JULES BORDET	4
INSTITUTE OF ONCOLOGY LJUBLJANA	4
ISTITUTO SUPERIORE DI SANITA	4
KATHOLIEKE UNIVERSITEIT LEUVEN	4
LUNDS UNIVERSITET	4
MEDICAL RESEARCH COUNCIL	4
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS	4
STICHTING KATHOLIEKE UNIVERSITEIT	4
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA	4
UNIVERSITA DEGLI STUDI DI PADOVA	4
CANCER RESEARCH UK	3
COMMISSARIAT A L'ENERGIE ATOMIQUE	3
DEUTSCHES KREBSFORSCHUNGSZENTRUM	3
ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM	3
EUROPEAN CANCER ORGANISATION	3
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL	3
IPSOGEN SAS	3
ISTITUTO EUROPEO DI ONCOLOGIA	3
MASARYKOVA UNIVERZITA	3
MEDICAL UNIVERSITY OF GDANSK	3
MEDIZINISCHE UNIVERSITAET WIEN	3
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS	3
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON	3
ST ANNA KINDERKREBSFORSCHUNG	3
STICHTING KATHOLIEKE UNIVERSITEIT MORE PARTICULARLY RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE	3
THE UNIVERSITY OF MANCHESTER	3
UNIVERSITA CATTOLICA DEL SACRO CUORE	3
UNIVERSITA DEGLI STUDI DI FIRENZE	3
UNIVERSITAETSKLINIKUM ESSEN	3
UNIVERSITY OF LEEDS	3
UPPSALA UNIVERSITET	3
WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTER	3
AARHUS UNIVERSITY HOSPITAL	2
ALMA CONSULTING GROUP SAS	2
ARTTIC	2
BENGURION UNIVERSITY OF THE NEGEV	2
CENTRE ANTICANCEREUX LEON BERARD	2
CENTRE NATIONAL FRANCOIS BACLESSE	2
CONSIGLIO NAZIONALE DELLE RICERCHE	2
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG	2
EBERHARD KARLS UNIVERSITAET TUEBINGEN	2
ECOLE NORMALE SUPERIEURE DE CACHAN	2
ENTE PER LE NUOVE TECNOLOGIE L'ENERGIA E L'AMBIENTE	2
EUROPEAN MOLECULAR BIOLOGY LABORATORY	2
EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY	2
F HOFFMANNLA ROCHE	2
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI	2
FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS	2
FUNDACIO CENTRE DE RECERCA EN EPIDEMIOLOGIA AMBIENTAL CREAL	2
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON	2
FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA	2
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA	2
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O	2
GBG FORSCHUNGS	2
HET NEDERLANDS KANKER INSTITUUT	2
HOSPITAL CLINIC PROVINCIAL DE BARCELONA	2
INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION	2
INSTITUT BERGONIE	2
INSTITUT CATALA D'ONCOLOGIA	2
INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO	2
ISTITUTO ORTOPEDICO RIZZOLI	2
JUSTUS LIEBIG UNIVERSITAET GIESSEN	2
KEOCYT SAS	2
KING'S COLLEGE LONDON	2
MEDIZINISCHE HOCHSCHULE HANNOVER	2
MEDIZINISCHE UNIVERSITAT GRAZ	2
OSLO UNIVERSITETSSYKEHUS HF	2
PHILIPPS UNIVERSITAET MARBURG	2
PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV	2
RAY SEARCH LABORATORIES AB	2
RUPRECHT KARLS UNIVERSITAET HEIDELBERG	2
SARCOMA PATIENTS EURONET EV	2
SEMMELWEIS EGYETEM	2
SIOP EUROPE	2
STATE INSTITUTION RESEARCH CENTER FOR RADIATION MEDICINE OF THE ACADEMY OF MEDICAL SCIENCES OF UKRAINE	2

Constancy:

Total number of partners:929

Partner loyalty:
Frequent Partner: (> 2 projects): 271
Rare Partner: 658

Frequent / Rare Partner Ratio: 0.41

Diversity:

Subjects:

Subject:	No:
HEALTH	30
MEDICINE	30
MEDICINE, HEALTH	28
LIFE SCIENCES	20
BIOTECHNOLOGY	14
SCIENTIFIC RESEARCH	12
MEDICAL BIOTECHNOLOGY	7
INNOVATION, TECHNOLOGY TRANSFER	5
COOPERATION	5
TECHNOLOGY TRANSFER	5
COORDINATION	5
COORDINATION, COOPERATION	5
INNOVATION	5
ENVIRONMENTAL PROTECTION	5
NUCLEAR FISSION	4
WASTE MANAGEMENT	3
SOCIAL ASPECTS	3
REGIONAL DEVELOPMENT	2
TRAINING	2
POLICIES	2
EDUCATION	2
INFORMATION PROCESSING, INFORMATION SYSTEMS	1
NUCLEAR FUSION	1
NETWORK TECHNOLOGIES	1
SAFETY	1
MATERIALS TECHNOLOGY	1
EVALUATION	1
INFORMATION SYSTEMS	1
ENERGY TRANSPORT	1
NANOTECHNOLOGY AND NANOSCIENCES	1
ENERGY STORAGE, ENERGY TRANSPORT	1
INFORMATION PROCESSING	1
ENERGY STORAGE	1

Diversity index:0.23

Categories:

Category:	No:
BIOLOGICAL SCIENCES	35
RTD HORIZONTAL TOPICS	19
PROTECTING MAN AND HIS ENVIRON	5
SOCIAL AND ECONOMIC CONCERNS	5
ENERGY	4
INDUSTRY AND TECHNOLOGY	3

Project overview:

Start date	Project	acronym	role	funding	partners
2020-01-01	4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening	4-IN THE LUNG RUN	participant	7.999.949	9
2019-06-01	Health effects of cArdiac fluoRoscopy and MOderN radIotherapy in paediatriCs	HARMONIC	participant	6.999.989	24
2019-01-01	Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.	ONCOBIOME	coordinator	14.994.551	18
2018-01-01	International Randomized Study Comparing personalized, Risk-Stratified to Standard Breast Cancer Screening In Women Aged 40-70	MyPeBS	participant	12.436.859	26
2017-12-01	A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.	CLINGLIO	participant	6.155.125	12
2017-11-01	Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research	SilkFUSION	participant	2.998.500	6
2017-01-01	ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064	ITCC-P4	participant	7.370.000	21
2016-12-01	Resistance mechanisms to tyrosine kinase inhibitors in solid tumors	TKI resistance	coordinator	1.500.000	1
2015-12-01	Training Network for the Immunotherapy of Cancer	IMMUTRAIN	participant	3.627.525	10
2015-09-01	ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer	ALKATRAS	participant	3.849.200	23
2013-10-01	EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma	EEC	participant	5.697.831	20
2013-06-01	Mutanome Engineered RNA Immuno-Therapy	MERIT	participant	5.964.250	5
2013-03-01	WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients	WINTHER	coordinator	2.998.355	11
2012-11-01	Non-Invasive Optical Biopsy for Cancer Assessment using ultra high resolution Full-Field Optical Coherence Tomography	CAReIOCA	participant	3.099.481	5
2012-10-01	Rational molecular Assessments and Innovative Drug Selection	RAIDS	participant	5.999.642	16
2012-09-01	Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients	CTCTRAP	participant	6.000.000	12
2012-08-01	Genetic epidemiological investigation into the association between endometriosis and cutaneous melanoma	MELENDO2	coordinator	268.555	1
2012-04-01	Biomaterials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway	BIOtrachea	participant	3.999.300	13
2012-02-01	Genome-based biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer	RESPONSIFY	participant	5.990.195	12
2011-12-01	European Clinical trials in Rare Sarcomas within an integrated translational trial network	EUROSARC	participant	5.953.832	18
2011-12-01	STRENGTHENING COOPERATION IN MOLECULAR BIOMEDICINE BETWEEN EU AND UKRAINE	COMBIOM	participant	455.499	3
2011-10-01	Cardiovascular Risk from Exposure to Low-dose and Low-dose-rate Ionizing Radiation	PROCARDIO	participant	2.998.387	13
2011-10-01	Cognitive and Cerebrovascular Effects Induced by Low Dose Ionising Radiation	CEREBRAD	participant	2.999.517	12
2011-04-01	Adaptive and innovative Radiation Treatment FOR improving Cancer patients treatment outcomE	ARTFORCE	participant	5.994.715	14
2011-02-01	PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies	PanCareSurFup	participant	5.993.695	17
2011-01-01	European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults	ENS@T-CANCER	participant	5.993.978	16
2011-01-01	EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS	ENCCA	participant	11.997.959	34
2011-01-01	Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics	PREDICT	participant	5.841.009	14
2011-01-01	A European Platform for Translational Cancer Research	EUROCANPLATFORM	participant	11.998.454	28
2011-01-01	Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis	CURELUNG	participant	2.965.749	11
2009-07-01	Integrated micro-nano-opto fluidic systems for high-content diagnosis and studies of rare cancer cells	CAMINEMS	participant	3.551.143	9
2009-01-01	Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies	INFLA-CARE	participant	11.999.889	22
2008-09-01	Prospective cohort studies of children with substantial medical diagnostic exposure	CHILD-MED-RAD	participant	279.931	9
2008-09-01	Oral off-patent oncology drugs for kids	03K	coordinator	5.228.003	9
2007-03-01	Colon and breast cancer diagnostics	COBRED	participant	2.985.102	9
2007-02-01	Molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity	CHEMORES	participant	8.707.358	19
2006-11-01	Selecting and validating drug targets from the human kinome for high risk pediatric cancers	KIDSCANCERKINOME	coordinator	3.415.414	11
2006-02-01	CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children	CONTICANET	participant	9.432.600	21
2005-12-01	European Prospective Investigation into Cancer, Chronic Diseases, Nutrition and Lifestyle	EPIC	participant	999.745	27
2005-12-01	Genetic and environmental determinants of melanoma: translation into behavioural change	GENOMEL	participant	10.452.723	22
2005-10-01	Feasibility Study for Coordination of National Cancer Research Activities	EUROCAN+PLUS	participant	3.000.000	17
2005-06-01	Radiation exposures at an early age: impact of genotype on breast cancer risk	GENE-RAD RISK	participant	2.000.000	12
2005-01-01	Dendritic cells for novel immmunotherapies	DC-THERA	participant	7.600.000	32
2004-07-01	European Mantle Cell Lymphoma Network: Tranlational determination of molecular prognostic factors and pharmacogenomics in a European interdisciplinary collaboration	EUROPEAN MCL NETWORK	participant	2.493.900	18
2004-05-01	METHODS AND ADVANCED EQUIPMENT FOR SIMULATION AND TREATMENT IN RADIO-ONCOLOGY	MAESTRO	participant	0	25
2004-03-01	Molecular Imaging for Biologically Optimised Cancer Therapy	BIOCARE	participant	6.000.000	21
2004-03-01	Translating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for improved treatment tailoring - TRANS-BIG	TRANS-BIG	participant	7.000.000	44
2004-01-01	Strengthen and develop scientific and technological excellence in research and therapy of leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration of the leading national leukemia networks and their interdisciplinary partner groups in Europe	EUROPEAN LEUKEMIANET	participant	6.000.000	177
2003-01-01	European standard operating procedures for electrochemotherapy and electrogenetherapy	ESOPE	coordinator	892.993	6
2002-12-01	Interplay among mitochondria and p53 family proteins during apoptosis induced by dna damage - a new strategy for cancer therapy	IMPALED	participant	1.983.547	7

overview shows latest 50 from 55 projects (2000-01-01 - 2020-12-31)
A full list of projects can be found here:

Alias institution names:

INSTITUT GUSTAVE ROUSSY

Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum